Atypical pathogens in hospitalized patients with community-acquired pneumonia: A worldwide perspective

Background: Empirical antibiotic coverage for atypical pathogens in community-acquired pneumonia (CAP) has long been debated, mainly because of a lack of epidemiological data. We aimed to assess both testing for atypical pathogens and their prevalence in hospitalized patients with CAP worldwide, especially in relation with disease severity. Methods: A secondary analysis of the GLIMP database, an international, multicentre, point-prevalence study of adult patients admitted for CAP in 222 hospitals across 6 continents in 2015, was performed. The study evaluated frequency of testing for atypical pathogens, including L. pneumophila, M. pneumoniae, C. pneumoniae, and their prevalence. Risk factors for testing and prevalence for atypical pathogens were assessed through univariate analysis. Results: Among 3702 CAP patients 1250 (33.8%) underwent at least one test for atypical pathogens. Testing varies greatly among countries and its frequency was higher in Europe than elsewhere (46.0% vs. 12.7%, respectively, p < 0.0001). Detection of L. pneumophila urinary antigen was the most common test performed worldwide (32.0%). Patients with severe CAP were less likely to be tested for both atypical pathogens considered together (30.5% vs. 35.0%, p = 0.009) and specifically for legionellosis (28.3% vs. 33.5%, p = 0.003) than the rest of the population. Similarly, L. pneumophila testing was lower in ICU patients. At least one atypical pathogen was isolated in 62 patients (4.7%), including M. pneumoniae (26/251 patients, 10.3%), L. pneumophila (30/1186 patients, 2.5%), and C. pneumoniae (8/228 patients, 3.5%). Patients with CAP due to atypical pathogens were significantly younger, showed less cardiovascular, renal, and metabolic comorbidities in comparison to adult patients hospitalized due to non-atypical pathogen CAP. Conclusions: Testing for atypical pathogens in patients admitted for CAP in poorly standardized in real life and does not mirror atypical prevalence in different settings. Further evidence on the impact of atypical pathogens, expecially in the low-income countries, is needed to guidelines implementation

Microbiological testing of adults hospitalised with community-acquired pneumonia: An international study

This study aimed to describe real-life microbiological testing of adults hospitalised with community-acquired pneumonia (CAP) and to assess concordance with the 2007 Infectious Diseases Society of America (IDSA)/American Thoracic Society (ATS) and 2011 European Respiratory Society (ERS) CAP guidelines. This was a cohort study based on the Global Initiative for Methicillin-resistant Staphylococcus aureus Pneumonia (GLIMP) database, which contains point-prevalence data on adults hospitalised with CAP across 54 countries during 2015. In total, 3702 patients were included. Testing was performed in 3217 patients, and included blood culture (71.1%), sputum culture (61.8%), Legionella urinary antigen test (30.1%), pneumococcal urinary antigen test (30.0%), viral testing (14.9%), acute-phase serology (8.8%), bronchoalveolar lavage culture (8.4%) and pleural fluid culture (3.2%). A pathogen was detected in 1173 (36.5%) patients. Testing attitudes varied significantly according to geography and disease severity. Testing was concordant with IDSA/ATS and ERS guidelines in 16.7% and 23.9% of patients, respectively. IDSA/ATS concordance was higher in Europe than in North America (21.5% versus 9.8%; p<0.01), while ERS concordance was higher in North America than in Europe (33.5% versus 19.5%; p<0.01). Testing practices of adults hospitalised with CAP varied significantly by geography and disease severity. There was a wide discordance between real-life testing practices and IDSA/ATS/ERS guideline recommendations

Prevalence and etiology of community-acquired pneumonia in immunocompromised patients

Background. The correct management of immunocompromised patients with pneumonia is debated. We evaluated the prevalence, risk factors, and characteristics of immunocompromised patients coming from the community with pneumonia. Methods. We conducted a secondary analysis of an international, multicenter study enrolling adult patients coming from the community with pneumonia and hospitalized in 222 hospitals in 54 countries worldwide. Risk factors for immunocompromise included AIDS, aplastic anemia, asplenia, hematological cancer, chemotherapy, neutropenia, biological drug use, lung transplantation, chronic steroid use, and solid tumor. Results. At least 1 risk factor for immunocompromise was recorded in 18% of the 3702 patients enrolled. The prevalences of risk factors significantly differed across continents and countries, with chronic steroid use (45%), hematological cancer (25%), and chemotherapy (22%) the most common. Among immunocompromised patients, community-acquired pneumonia (CAP) pathogens were the most frequently identified, and prevalences did not differ from those in immunocompetent patients. Risk factors for immunocompromise were independently associated with neither Pseudomonas aeruginosa nor non\u2013community-acquired bacteria. Specific risk factors were independently associated with fungal infections (odds ratio for AIDS and hematological cancer, 15.10 and 4.65, respectively; both P = .001), mycobacterial infections (AIDS; P = .006), and viral infections other than influenza (hematological cancer, 5.49; P < .001). Conclusions. Our findings could be considered by clinicians in prescribing empiric antibiotic therapy for CAP in immunocompromised patients. Patients with AIDS and hematological cancer admitted with CAP may have higher prevalences of fungi, mycobacteria, and noninfluenza viruses

Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia:a Multinational Point Prevalence Study of Hospitalised Patients

Pseudornonas aeruginosa is a challenging bacterium to treat due to its intrinsic resistance to the antibiotics used most frequently in patients with community-acquired pneumonia (CAP). Data about the global burden and risk factors associated with P. aeruginosa-CAP are limited. We assessed the multinational burden and specific risk factors associated with P. aeruginosa-CAP. We enrolled 3193 patients in 54 countries with confirmed diagnosis of CAP who underwent microbiological testing at admission. Prevalence was calculated according to the identification of P. aeruginosa. Logistic regression analysis was used to identify risk factors for antibiotic-susceptible and antibiotic-resistant P. aeruginosa-CAP. The prevalence of P. aeruginosa and antibiotic-resistant P. aeruginosa-CAP was 4.2% and 2.0%, respectively. The rate of P. aeruginosa CAP in patients with prior infection/colonisation due to P. aeruginosa and at least one of the three independently associated chronic lung diseases (i.e. tracheostomy, bronchiectasis and/or very severe chronic obstructive pulmonary disease) was 67%. In contrast, the rate of P. aeruginosa-CAP was 2% in patients without prior P. aeruginosa infection/colonisation and none of the selected chronic lung diseases. The multinational prevalence of P. aeruginosa-CAP is low. The risk factors identified in this study may guide healthcare professionals in deciding empirical antibiotic coverage for CAP patients

Down from the treetops: Red langur (Presbytis rubicunda) terrestrial behaviour

Using direct observations and camera traps at eight sites across Indonesian Borneo we show how red langurs (Presbytis rubicunda) are more terrestrial than previously believed, regularly coming to the ground. This unusual behavior has been found at six of the eight sites surveyed. We find that red langurs come to the ground more frequently in disturbed forests, specifically ones which have been impacted by logging, fire, and hunting, though more data are needed to confirm this as a direct correlation. We also found a trend towards decreased ground use with increased elevation of the habitat. When on the ground, red langurs are predominantly engaged in feeding (50% direct observations, 61% camera traps) and traveling (29% direct observations, 13% camera traps). Red langurs are found on the ground throughout the day, at similar times to activity periods of the apex predator, the Sunda clouded leopard (Neofelis diardi). We suggest that ground use by red langurs could be an adaptation to disturbed forest to exploit additional food sources and to facilitate travel

Primate responses to changing environments in the anthropocene

Most primates have slow life-histories and long generation times. Because environmental change is occurring at an unprecedented rate, gene-based adaptations are unlikely to evolve fast enough to offer successful responses to these changes. The paper reviews the most common types of habitat/landscape alterations, the extent of human-primate interactions, and the impact of climate change. It demonstrates how understanding behavioural flexibility as a response to environmental change will be crucial to optimize conservation efforts by constructing informed management plans. Comparisons across species, space, and time can be used to draw generalizations about primate responses to environmental change while considering their behavioural flexibility

Targeting integrin alpha-v-beta-6 in Lung Cancer

Lung cancer is the leading cause of cancer related death and third most common cancer in the UK and worldwide. The integrin αvβ6 is known to promote multiple pro-tumorigenic processes. Weak or absent on most normal tissues αvβ6 is up-regulated during tissue remodelling including chronic inflammation, fibrosis and cancer. Strong expression has been associated with significantly poorer survival in many cancers, including the 54% of non-small cell lung cancers (NSCLC) reported to express αvβ6. Preclinical studies of other cancers have shown antibody targeting of αvβ6 can suppress tumour growth and thus αvβ6 represents a promising therapeutic target for NSCLC. The aims of this project are to investigate the role of αvβ6 in lung cancer and to explore antibody blockade as a potential therapeutic strategy. 25 lung carcinoma cell lines were collected and characterised. Integrin αvβ6 expression was determined by flow cytometry and western blot analysis - 11 cell lines were found to be positive for β6 protein, 2 of which were weakly positive, with small subpopulations of β6 expressing cells. Mini-organotypic assays performed on the 9 grossly positive lines revealed that these lung cancer cells were only seen to invade through gels in the presence of fibroblasts. Moreover, only 4 of the lung cancer cell lines invaded through the gel when they were seeded with fibroblasts, the other 5 only invaded when the fibroblasts were embedded in the gel. In the 3 cell lines that were tested with antibody-blockade (53A2) invasion was been shown to be β6 dependent. Matrigel invasion assays confirmed this finding of β6 dependent invasion, where again blockade with specific antibody against β6 significantly reduces invasion. Migration has also been shown to be β6 dependent, as antibody blockade has significantly reduced the migration towards Latency associated Peptide of TGFβ1. Therefore, in β6 positive lung cancer invasion and migration are β6 dependent. Having identified that the KRasLSLG12D+/-P53fl/fl (KP) lung cancer mouse model expresses αvβ6 on tumours, I went on to breed this model with a β6 knockout mouse model to create a new model of lung cancer (KPI). A genetic ‘ageing’ study allowed a comparison of the three cohorts of homozygous, heterozygous and wildtype for αvβ6 expression. This showed that complete loss of integrin αvβ6 resulted in faster tumour growth and poorer survival. This is likely explained by the fact that αvβ6 can activate latent TGF-β and that TGF-β can act both as tumour suppressor in the early development of cancer and as a tumour promoter in established disease. This experiment allowed an opportunity to study in detail the development of lung cancer using MRI, and to develop a tumour staging system to describe and treat disease in a similar method to that used in patients. It also demonstrated that αvβ6-specific imaging can reliably be used to detect NSCLC. In vivo studies with β6 blocking antibody showed no significant reduction in lung cancer in KPI mice even when combined with conventional chemotherapy (cisplatin). Overall the data suggest additional research is required to fully appreciate what biology is controlled by αvβ6 at different stages of lung cancer development